28 May 2020
3pm - 4pm BST
During this hour-long panel discussion, we will investigate the impact of the COVID-19 pandemic and the ensuing lockdown on early clinical development activities. Using real life examples, we will discuss the practicalities of starting/continuing clinical studies in a dynamic patient and regulatory environment, and the risks of beginning prematurely or starting too late.
tranScrip’s experts will be joined by other pharmaceutical physicians and leading healthcare professionals who will share their views on how the ongoing COVID-19 pandemic is impacting their clinical development activities.
We encourage attendees to participate and share insights as well as comment and ask questions to make this an interactive discussion.
We hope you can join us!